Assembly Biosciences, Inc. Payments for Restructuring
Assembly Biosciences, Inc. (ASMB) reported Payments for Restructuring of $599.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2024-03-28
- Assembly Biosciences, Inc. payments for restructuring for the quarter ending 2023-12-31 was $0.00.
- Assembly Biosciences, Inc. payments for restructuring for the quarter ending 2023-09-30 was $99.00K, a 76.81% decline year-over-year.
- Assembly Biosciences, Inc. payments for restructuring for the quarter ending 2023-06-30 was $245.00K.
- Assembly Biosciences, Inc. payments for restructuring for the quarter ending 2023-03-31 was $255.00K.
- Assembly Biosciences, Inc. payments for restructuring for fiscal 2023 was $599.00K, a 53.20% decline from fiscal 2022.
- Assembly Biosciences, Inc. payments for restructuring for fiscal 2022 was $1.28M, a 77.84% decline from fiscal 2021.
- Assembly Biosciences, Inc. payments for restructuring for fiscal 2021 was $5.78M, a 225.72% increase from fiscal 2020.
- Assembly Biosciences, Inc. payments for restructuring for fiscal 2020 was $1.77M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $99.00K derived: sum of 2 quarters · filed 2024-03-28 | $344.00K derived: sum of 3 quarters · filed 2024-03-28 | $599.00K 10-K · filed 2024-03-28 |
| 2023-09-30 | $99.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $344.00K derived: sum of 2 quarters · filed 2023-11-08 | $599.00K 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $245.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $500.00K 10-Q · filed 2023-08-09 | ||
| 2023-03-31 | $255.00K 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $1.28M 10-K · filed 2024-03-28 | |||
| 2022-09-30 | $427.00K 10-Q · filed 2022-11-08 | |||
| 2021-12-31 | $232.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $683.00K derived: sum of 2 quarters · filed 2023-03-22 | $1.25M derived: sum of 3 quarters · filed 2023-03-22 | $5.78M 10-K · filed 2023-03-22 |
| 2021-09-30 | $451.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $1.01M derived: sum of 2 quarters · filed 2021-11-04 | $5.54M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $563.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $5.09M 10-Q · filed 2021-08-05 | ||
| 2021-03-31 | $4.53M 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $1.77M 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |